Ferring Pharmaceuticals and SK Pharmteco Enter into Commercial Gene Therapy Manufacturing Deal
After Adstiladrin's FDA approval in late 2022, Ferring Pharmaceuticals finally established unfettered supply of the bladder cancer gene therapy earlier this year. Now, the company has locked down a long-term supplier in SK pharmteco.
Ferring Adds Three New Studies to Non-Muscle Invasive Bladder Cancer Clinical Trial Program With ADSTILADRIN® (nadofaragene firadenovec-vncg)
Ferring Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASIPP 2024
Ferring`s Zomacton (Somatropin) Receives Suppl Approvals in the U.S
Phase 4 Study Evaluating Use of ADSTILADRIN® (nadofaragene firadenovec-vncg) in Real-World Setting
Ferring Announces Full Availability of ADSTILADRIN in the U.S.
As waves of layoffs continue to hit the biopharma industry, Ferring Pharmaceuticals is trimming its headcount by 134 across its two U.S. locations.
Ferring and PharmaBiome Enter Into a New Microbiome R&D Collaboration